The USPTO issued a third patent covering fundamental aspects of the CRISPR-Cas9 technology to The Regents of the University of California, the University of Vienna and Emmanuelle Charpentier, strengthening the group's patent position in the highly complex IP landscape.
privacy policy | terms of use | contact us | advertise | pharma jobs | pharma blogs | facebook | twitter
Copyright © 2025,